KR970015602A - 사람 위암에 대한 면역 반응을 유도할 수 있는 펩타이드 및 이러한 펩타이드를 함유하는 사람의 위암 예방 또는 치료용 제제 - Google Patents
사람 위암에 대한 면역 반응을 유도할 수 있는 펩타이드 및 이러한 펩타이드를 함유하는 사람의 위암 예방 또는 치료용 제제 Download PDFInfo
- Publication number
- KR970015602A KR970015602A KR1019960042331A KR19960042331A KR970015602A KR 970015602 A KR970015602 A KR 970015602A KR 1019960042331 A KR1019960042331 A KR 1019960042331A KR 19960042331 A KR19960042331 A KR 19960042331A KR 970015602 A KR970015602 A KR 970015602A
- Authority
- KR
- South Korea
- Prior art keywords
- gastric cancer
- peptide
- hla
- preventing
- amino acid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 18
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 15
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 15
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 15
- 230000001939 inductive effect Effects 0.000 title claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 6
- 230000028993 immune response Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 6
- 210000004027 cell Anatomy 0.000 claims abstract 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- 108010018475 HLA-A31 antigen Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 claims 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 3
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
사람 위암에 대해 효과적인 CTL을 유도하는 펩타이드가 제공된다.
특정 아미노산 서열을 갖는 펩타이드는 위암 세포를 표적화하는 세포독성 T세포를 유도한다. 따라서, 이러한 펩타이드가 위암 예방 또는 치료용 제제인 것으로 기대되어진다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 역상 HPLC 칼럼에서 HST-2 위암 세포로부터 HLA-결합된 펩타이드의 용출 패턴을 나타낸다. 여기서, 직선은 아세토니트릴 농도를, 곡선을 각각의 농도에서 OD210에서의 흡광도 값을 나타낸다.
제2도는 HST-2-유도된 HLA-결합된 펩타이드를 사용하는 경우 Tc-HST-2의 특이적 세포독성을 나타내는 그래프이다. 여기서 ○는 HST-2를 사용하는 경우의 특이적 세포독성을 나타내고, ◆는 표적세포로서, HLA-A31-양성 KG-1 세포를 사용하는 경우의 세포독성을 나타낸다. 모든 시험은 표적 세포: CTL의 비가 1:100인 상태에서 수행한다.
제3도는 역상 HPLC 칼럼에 의한, 제2도에 나타난 CTL 유도성을 보이는 12번째 분획의 용출 패턴이다. 여기서, 선은 아세토니트릴의 농도를 나타내고, 곡선은 각각의 농도에서의 OD210에서의 흡광도를 나타낸다.
Claims (11)
- HLA(사람 임파구 항원) 분자에 결합하여, 위암 세포를 표적화하는 세포독성 T세포를 유도할 수 있는, 사람 위암 세포 중에 존재하는 위암 항원 단백질의 단편인 펩타이드.
- 제1항에 있어서, HLA 분자가 HLA-A31인 펩타이드.
- 제1항에 있어서, 서열표의 서열 확인 번호 1의 아미노산 서열을 갖는 펩타이드.
- 제1항에 있어서, 위암 세표를 표적화하는 세포독성 T세포를 보다 효율적으로 유도할 수 있게 하기 위하여, 서열표의 서열 확인 번호 1의 아미노산 서열의 일부를 변형시킴으로써 수득된 아미노산 서열을 갖는 펩타이드.
- 제4항에 있어서, 서열표의 서열 확인 번호 2의 아미노산 서열을 갖는 펩타이드.
- HLA 분자에 결합하여, 위암 세표를 표적화하는 세포독성 T세포를 유도할 수 있는, 사람 위암 세포 중에 존재하는 위암 항원 단백질의 단편인 펩타이드를 함유하는, 사람 위암 예방용 또는 치료용 제제.
- 제6항에 있어서, HLA 분자가 HLA-A31인 제제.
- 제6항에 있어서, 상기 펩타이드가 서열표의 서열 확인 번호 1 또는 2의 아미노산 서열을 갖는 제제.
- 제1항 또는 제4항의 펩타이드를 암호화하는 DNA.
- 제3항 또는 제5항의 펩타이드를 암호화하는 DNA.
- 제9항 또는 제10항의 DNA를 갖는 재조합 바이러스 또는 재조합 세균을 함유하는, 사람 위암 예방용 또는 치료용 백신.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25349195 | 1995-09-29 | ||
| JP95-253491 | 1995-09-29 | ||
| JP8217140A JPH09151200A (ja) | 1995-09-29 | 1996-08-19 | ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤 |
| JP96-217140 | 1996-08-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR970015602A true KR970015602A (ko) | 1997-04-28 |
| KR100378901B1 KR100378901B1 (ko) | 2003-06-11 |
Family
ID=26521838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960042331A KR100378901B1 (ko) | 1995-09-29 | 1996-09-25 | 사람위암에대한면역반응을유도할수있는펩타이드및이러한펩타이드를함유하는사람위암의예방또는치료용제제 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US5837248A (ko) |
| EP (1) | EP0770624B1 (ko) |
| JP (1) | JPH09151200A (ko) |
| KR (1) | KR100378901B1 (ko) |
| CN (1) | CN1158856A (ko) |
| DE (1) | DE69627780T2 (ko) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09151200A (ja) * | 1995-09-29 | 1997-06-10 | Ajinomoto Co Inc | ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤 |
| US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| WO1999067288A1 (fr) | 1998-06-25 | 1999-12-29 | Sumitomo Pharmaceuticals Company, Limited | Peptides d'antigenes tumoraux provenant de la cyclophiline b |
| JP2000023673A (ja) | 1998-07-13 | 2000-01-25 | Ajinomoto Co Inc | ヒト胃癌抗原遺伝子および胃癌抗原蛋白質 |
| WO2000018435A1 (de) * | 1998-09-25 | 2000-04-06 | Horst Lindhofer | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung |
| MEP42108A (en) | 1998-10-23 | 2011-02-10 | Kiren Amgen Inc | Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity |
| EP1416919A1 (en) * | 2001-07-17 | 2004-05-12 | Teva Pharmaceutical Industries Ltd. | Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| US20030206916A1 (en) * | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
| US20050026871A1 (en) * | 2002-07-17 | 2005-02-03 | Moshe Flashner-Barak | Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative |
| EP1773400A2 (en) | 2004-07-08 | 2007-04-18 | Amgen Inc. | Therapeutic peptides |
| EP1797127B1 (en) | 2004-09-24 | 2017-06-14 | Amgen Inc. | Modified fc molecules |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| CN104914242B (zh) * | 2014-09-29 | 2017-08-11 | 深圳华大基因科技服务有限公司 | 用于癌症诊断和治疗的方法和组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2860875D1 (en) * | 1977-09-28 | 1981-10-15 | Nat Res Dev | Immunological preparations incorporating mhc antigens and their production |
| DE3377363D1 (en) * | 1982-03-31 | 1988-08-18 | Ajinomoto Kk | Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells |
| US5468481A (en) * | 1988-06-23 | 1995-11-21 | Amergen, Inc. | MHC class II-peptide conjugates useful in ameliorating autoimmunity |
| JP3255699B2 (ja) * | 1992-04-23 | 2002-02-12 | 味の素株式会社 | ヒトＩＬ−２レセプターγ鎖分子 |
| US5550214A (en) * | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
| JPH09151200A (ja) * | 1995-09-29 | 1997-06-10 | Ajinomoto Co Inc | ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤 |
| JP2000023673A (ja) * | 1998-07-13 | 2000-01-25 | Ajinomoto Co Inc | ヒト胃癌抗原遺伝子および胃癌抗原蛋白質 |
-
1996
- 1996-08-19 JP JP8217140A patent/JPH09151200A/ja active Pending
- 1996-09-25 KR KR1019960042331A patent/KR100378901B1/ko not_active IP Right Cessation
- 1996-09-27 CN CN96121195A patent/CN1158856A/zh active Pending
- 1996-09-30 DE DE69627780T patent/DE69627780T2/de not_active Expired - Fee Related
- 1996-09-30 EP EP96307163A patent/EP0770624B1/en not_active Expired - Lifetime
- 1996-09-30 US US08/723,116 patent/US5837248A/en not_active Expired - Lifetime
-
1998
- 1998-06-24 US US09/103,808 patent/US6368852B1/en not_active Expired - Fee Related
-
2002
- 2002-01-08 US US10/038,899 patent/US20030186406A1/en not_active Abandoned
-
2005
- 2005-02-07 US US11/050,679 patent/US20050208064A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0770624B1 (en) | 2003-05-02 |
| US20030186406A1 (en) | 2003-10-02 |
| EP0770624A3 (en) | 1998-12-23 |
| US20050208064A1 (en) | 2005-09-22 |
| EP0770624A2 (en) | 1997-05-02 |
| US5837248A (en) | 1998-11-17 |
| US6368852B1 (en) | 2002-04-09 |
| CN1158856A (zh) | 1997-09-10 |
| KR100378901B1 (ko) | 2003-06-11 |
| JPH09151200A (ja) | 1997-06-10 |
| DE69627780D1 (de) | 2003-06-05 |
| DE69627780T2 (de) | 2004-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR970015602A (ko) | 사람 위암에 대한 면역 반응을 유도할 수 있는 펩타이드 및 이러한 펩타이드를 함유하는 사람의 위암 예방 또는 치료용 제제 | |
| Yan et al. | Synthesis of peptides and proteins without cysteine residues by native chemical ligation combined with desulfurization | |
| ATE382055T1 (de) | Wnt-1 verwandte polypeptide und dafür kodierende nukleinsäuren | |
| KR960704923A (ko) | HIV에 대한 면역응답을 유도할 수 있는 펩티드 및 그 펩티드를 함유하는 항 AIDS 예방·치료제(Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS) | |
| HUP0004639A2 (hu) | Chlamydia fehérje, génszekvencia és ezek alkalmazása | |
| WO2002044215A3 (en) | Hybrid antibodies | |
| DK1175909T3 (da) | Terapeutiske sammensætninger af antistoffer og antisense-nukleinsyrer mod Serrate | |
| NO20043891L (no) | Anti-A-beta-antistoffer og deres anvendelse | |
| KR900701836A (ko) | 신규 hiv 단백질 및 aids의 진단, 예방 또는 치료에 유용한 펩티드 | |
| ATE257160T1 (de) | Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde | |
| DE69636938D1 (de) | HYBRID AUS INTERFERON-alpha UND IMMUNGLOBULIN Fc-FRAGMENT VERBUNDEN DURCH EIN NICHT IMMUNOGENES PEPTID | |
| CY1109881T1 (el) | Νεοαγγειακα-συγκεκριμενα πεπτιδια | |
| WO1999003881A3 (fr) | Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique | |
| DE68927379D1 (de) | Plättchen blockierende peptide | |
| CA2165458A1 (fr) | Proteines intracellulaires de liaison (pil) et leurs utilisations | |
| BRPI0406745A (pt) | Formulações parenterais de peptìdeos para o tratamento de lupus eritematoso sistêmico | |
| ATE371671T1 (de) | Rekombinantes allergen, seine fragmente und die damit korrespondierenden dna-moleküle, vektoren, und diese dna-moleküle enthaltenden wirte, und dignostische und therapeutische verwendungen besagter allergene und fragmente | |
| DE69931482D1 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| Browning et al. | Disulfide scrambling of interleukin-2: HPLC resolution of the three possible isomers | |
| Capiau et al. | Protein-chemical analysis of pertussis toxin reveals homology between the subunits S2 and S3, between S1 and the A chains of enterotoxins of Vibrio cholerae and Escherichia coli and identifies S2 as the haptoglobin-binding subunit | |
| Milstein et al. | Disulphide bridges of the heavy chain of human immunoglobulin G2 | |
| RU2002126396A (ru) | Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека | |
| Aird et al. | Amino acid sequence of the basic subunit of Mojave toxin from the venom of the Mojave rattlesnake (Crotalus s. scutulatus) | |
| Gariepy et al. | A common antigenic determinant found in two functionally unrelated toxins. | |
| RU2215005C2 (ru) | Регуляторные/развернутые пептиды эзрина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20070319 Year of fee payment: 5 |
|
| LAPS | Lapse due to unpaid annual fee |